WST Stock - West Pharmaceutical Services, Inc.
Unlock GoAI Insights for WST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.89B | $2.95B | $2.89B | $2.83B | $2.15B |
| Gross Profit | $1.00B | $1.13B | $1.14B | $1.17B | $767.90M |
| Gross Margin | 34.6% | 38.4% | 39.5% | 41.5% | 35.8% |
| Operating Income | $594.60M | $710.90M | $763.50M | $758.70M | $419.00M |
| Net Income | $492.70M | $593.40M | $585.90M | $661.80M | $346.20M |
| Net Margin | 17.0% | 20.1% | 20.3% | 23.4% | 16.1% |
| EPS | $6.75 | $7.99 | $7.88 | $8.90 | $4.68 |
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 2nd 2025 | Morgan Stanley | Initiation | Equal Weight | $285 |
| September 15th 2025 | Rothschild & Co Redburn | Initiation | Buy | $311 |
| June 24th 2025 | Barclays | Initiation | Equal Weight | $245 |
| March 18th 2025 | Evercore ISI | Initiation | Outperform | $275 |
| February 14th 2025 | Deutsche Bank | Upgrade | Buy | $250 |
| January 8th 2025 | Citigroup | Initiation | Buy | $400 |
| December 13th 2024 | Wolfe Research | Initiation | Peer Perform | - |
| December 12th 2024 | UBS | Upgrade | Buy | $390← $350 |
| February 7th 2024 | Jefferies | Upgrade | Buy | $536← $323 |
| June 16th 2023 | BofA Securities | Upgrade | Buy | $405← $390 |
| April 11th 2023 | Stephens | Upgrade | Overweight | $400← $330 |
| December 14th 2022 | Deutsche Bank | Initiation | Hold | $250 |
| November 30th 2022 | UBS | Initiation | Neutral | $250 |
| October 28th 2022 | BofA Securities | Downgrade | Neutral | $250← $385 |
Earnings History & Surprises
WSTEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 22, 2026 | — | — | — | — |
Q1 2026 | Feb 12, 2026 | $1.83 | — | — | — |
Q4 2025 | Oct 23, 2025 | $1.67 | $1.96 | +17.4% | ✓ BEAT |
Q3 2025 | Jul 24, 2025 | $1.51 | $1.84 | +21.9% | ✓ BEAT |
Q2 2025 | Apr 24, 2025 | $1.22 | $1.45 | +18.9% | ✓ BEAT |
Q1 2025 | Feb 13, 2025 | $1.71 | $1.82 | +6.4% | ✓ BEAT |
Q4 2024 | Oct 24, 2024 | $1.50 | $1.85 | +23.3% | ✓ BEAT |
Q3 2024 | Jul 25, 2024 | $1.74 | $1.52 | -12.6% | ✗ MISS |
Q2 2024 | Apr 25, 2024 | $1.26 | $1.56 | +23.8% | ✓ BEAT |
Q1 2024 | Feb 15, 2024 | $1.78 | $1.83 | +2.8% | ✓ BEAT |
Q4 2023 | Oct 26, 2023 | $1.86 | $2.16 | +16.1% | ✓ BEAT |
Q3 2023 | Jul 27, 2023 | $1.93 | $2.11 | +9.3% | ✓ BEAT |
Q2 2023 | Apr 27, 2023 | $1.67 | $1.98 | +18.6% | ✓ BEAT |
Q1 2023 | Feb 16, 2023 | $1.38 | $1.77 | +28.3% | ✓ BEAT |
Q4 2022 | Oct 27, 2022 | $2.12 | $2.03 | -4.2% | ✗ MISS |
Q3 2022 | Jul 28, 2022 | $2.21 | $2.47 | +11.8% | ✓ BEAT |
Q2 2022 | Apr 28, 2022 | $2.12 | $2.30 | +8.5% | ✓ BEAT |
Q1 2022 | Feb 17, 2022 | $1.92 | $2.04 | +6.3% | ✓ BEAT |
Q4 2021 | Oct 28, 2021 | $1.80 | $2.06 | +14.4% | ✓ BEAT |
Q3 2021 | Jul 29, 2021 | $1.74 | $2.46 | +41.4% | ✓ BEAT |
Latest News
Morgan Stanley Initiates Coverage On West Pharmaceutical Servs with Equal-Weight Rating, Announces Price Target of $285
➖ NeutralTD Cowen Initiates Coverage On West Pharmaceutical Servs with Buy Rating, Announces Price Target of $350
📈 PositiveBarclays Maintains Equal-Weight on West Pharmaceutical Servs, Raises Price Target to $325
📈 Positive1. West Pharmaceutical Unveils New Prefillable Syringe System for Biologics and Vaccines, Launches Synchrony Syringe Platform, Set for 2026 Release
📈 PositiveUBS Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $355
📈 PositiveKeybanc Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $350
📈 PositiveEvercore ISI Group Maintains Outperform on West Pharmaceutical Servs, Raises Price Target to $390
📈 PositiveWest Pharmaceutical Services shares are trading higher after the company reported a Q3 earnings beat and raised its FY2025 EPS and sales guidance above estimates.
📈 PositiveWest Pharmaceutical Servs Raises FY2025 Adj EPS Guidance from $6.65-$6.85 to $7.06-$7.11 vs $6.77 Est; Raises FY2025 Sales Guidance from $3.040B-$3.060B to $3.060B-$3.070B vs $3.050B Est
📈 PositiveWest Pharmaceutical Servs Raises FY2025 GAAP EPS Guidance from $6.36-$6.56 to $6.75-$6.80 vs $6.53 Est
📈 PositiveWest Pharmaceutical Servs Q3 Adj. EPS $1.96 Beats $1.68 Estimate, Sales $804.600M Beat $787.929M Estimate
📈 PositiveBarclays Maintains Equal-Weight on West Pharmaceutical Servs, Raises Price Target to $275
➖ NeutralRothschild & Co Initiates Coverage On West Pharmaceutical Servs with Buy Rating, Announces Price Target of $311
📈 PositiveWest Pharmaceutical rises on upbeat results, guidance raise
📈 PositiveFrequently Asked Questions about WST
What is WST's current stock price?
What is the analyst price target for WST?
What sector is West Pharmaceutical Services, Inc. in?
What is WST's market cap?
Does WST pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to WST for comparison